Success Metrics

Clinical Success Rate
80.6%

Based on 25 completed trials

Completion Rate
81%(25/31)
Active Trials
27(42%)
Results Posted
88%(22 trials)
Terminated
6(9%)

Phase Distribution

Ph phase_2
13
20%
Ph not_applicable
3
5%
Ph phase_4
13
20%
Ph phase_3
23
35%
Ph early_phase_1
1
2%
Ph phase_1
7
11%

Phase Distribution

8

Early Stage

13

Mid Stage

36

Late Stage

Phase Distribution60 total trials
Early Phase 1First-in-human
1(1.7%)
Phase 1Safety & dosage
7(11.7%)
Phase 2Efficacy & side effects
13(21.7%)
Phase 3Large-scale testing
23(38.3%)
Phase 4Post-market surveillance
13(21.7%)
N/ANon-phased studies
3(5.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

75.8%

25 of 33 finished

Non-Completion Rate

24.2%

8 ended early

Currently Active

27

trials recruiting

Total Trials

65

all time

Status Distribution
Active(31)
Completed(25)
Terminated(8)
Other(1)

Detailed Status

Completed25
Recruiting15
Active, not recruiting12
Terminated6
Not yet recruiting4
Withdrawn2

Development Timeline

Analytics

Development Status

Total Trials
65
Active
27
Success Rate
80.6%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (1.7%)
Phase 17 (11.7%)
Phase 213 (21.7%)
Phase 323 (38.3%)
Phase 413 (21.7%)
N/A3 (5.0%)

Trials by Status

not_yet_recruiting46%
active_not_recruiting1218%
unknown12%
completed2538%
terminated69%
recruiting1523%
withdrawn23%

Recent Activity

Clinical Trials (65)

Showing 20 of 65 trialsScroll for more
NCT06916390Phase 4

GUselkumAb inteRvention and DIet evaluAtioN for Pouchitis

Recruiting
NCT06039189Phase 3

Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis

Completed
NCT05347095Phase 3

A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease

Active Not Recruiting
NCT07532486Not Applicable

A Study to Evaluate Comparative Efficacy and Safety of Guselkumab in High-dose and Extended-interval Versus Standard-dose in Chinese Participants of Moderate-to-severe Plaque Psoriasis

Recruiting
NCT07528040

An Observational, Multicenter Study to Evaluate the Effectiveness of Guselkumab for the Treatment of Participants With Crohn's Disease After Surgical Resection

Not Yet Recruiting
NCT07141004Phase 4

A Study of Guselkumab Administered Subcutaneously in Treatment of Indian Participants With Psoriatic Arthritis (PsA)

Recruiting
NCT04033445Phase 2

A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis

Active Not Recruiting
NCT06408935Phase 3

Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients

Recruiting
NCT04882098Phase 3

A Study of Guselkumab in Participants With Active Psoriatic Arthritis

Active Not Recruiting
NCT05242484Phase 2

A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis

Active Not Recruiting
NCT05242471Phase 2

A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease

Active Not Recruiting
NCT04936308Phase 3

Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent

Active Not Recruiting
NCT05049798

A Study of Guselkumab and Interleukin-17 (IL-17) Inhibitor Therapies in Participants With Psoriatic Arthritis in Routine Clinical Practice

Active Not Recruiting
NCT03451851Phase 3

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants

Active Not Recruiting
NCT05923073Phase 3

A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease

Recruiting
NCT05071664Phase 2

A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoriatic Arthritis

Completed
NCT05083182Phase 3

A Study of Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis

Active Not Recruiting
NCT04929210Phase 4

A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease

Active Not Recruiting
NCT07499232Phase 3

A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease

Not Yet Recruiting
NCT06663332Phase 3

A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants

Recruiting

Drug Details

Intervention Type
DRUG
Total Trials
65